2024
Current state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions
Jacobs J, Booth G, Raza S, Clark L, Fasano R, Gavriilaki E, Abels E, Binns T, Duque M, McQuilten Z, Mingot‐Castellano M, Savani B, Sharma D, Tran M, Tormey C, Moise K, Bloch E, Adkins B. Current state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions. American Journal Of Hematology 2024 PMID: 39324647, DOI: 10.1002/ajh.27487.Peer-Reviewed Original ResearchHematological conditionsFcRn inhibitorsClinical trialsStandardized treatment algorithmClinical trial dataNeonatal Fc receptorIn vivo studiesImmune-mediatedHematological disordersTreatment algorithmTransports IgGAdverse eventsImmunomodulatory/immunosuppressive therapiesIgG levelsPatient populationProtective IgGFc receptorsTherapeutic strategiesMucosal surfacesRheumatologic conditionsIgG antibodiesImmunoglobulin isotypesTrial dataIgGFcRnA multi‐institutional survey of apheresis services among institutions in the United States
Yurtsever N, Jacobs J, Booth G, Schwartz J, Park Y, Woo J, Lauro D, Torres S, Ward D, Stephens L, Allen E, Tormey C, Adkins B. A multi‐institutional survey of apheresis services among institutions in the United States. Journal Of Clinical Apheresis 2024, 39: e22138. PMID: 38979705, DOI: 10.1002/jca.22138.Peer-Reviewed Original ResearchConceptsTherapeutic plasma exchangeRed blood cell exchangeCell collectionSpectra Optia apheresis systemMulti-institutional surveyHematopoietic progenitor cell collectionProgenitor cell collectionUS academic centersCAR-TPlasma exchangeApheresis therapyGene therapyTransfusion medicine serviceCellular therapyApheresis practiceApheresis systemCell exchangeAcademic medical centerClinical trialsAcademic centersHPC-AApheresisMedical CenterTherapyCoronavirus disease 2019
2021
Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
Goshua G, Sinha P, Hendrickson J, Tormey C, Bendapudi PK, Lee AI. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood 2021, 137: 969-976. PMID: 33280030, PMCID: PMC7918179, DOI: 10.1182/blood.2020006052.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCombined Modality TherapyCost-Benefit AnalysisDecision TreesDrug CostsDrug Therapy, CombinationFemaleFibrinolytic AgentsHemorrhageHumansImmunosuppressive AgentsLength of StayMaleMarkov ChainsMiddle AgedModels, EconomicMulticenter Studies as TopicPlasma ExchangePurpura, Thrombotic ThrombocytopenicRecurrenceRituximabSingle-Domain AntibodiesStandard of CareUnited StatesYoung AdultConceptsIncremental cost-effectiveness ratioThrombotic thrombocytopenic purpuraTherapeutic plasma exchangeVon Willebrand factorRelapse rateThrombocytopenic purpuraClinical trialsMajor randomized clinical trialsThrombotic microangiopathy leadingEnd-organ damageWillebrand factorPlatelet count recoveryRandomized clinical trialsHealth system costsOne-way sensitivity analysesCost-effectiveness ratioLife-threatening diseaseProbabilistic sensitivity analysesCost-effectiveness analysisHospital lengthCount recoveryPlasma exchangeTPE treatmentTTP patientsImmunomodulatory agents
2013
Pathology Consultation on Monitoring Direct Thrombin Inhibitors and Overcoming Their Effects in Bleeding Patients
Winkler AM, Tormey CA. Pathology Consultation on Monitoring Direct Thrombin Inhibitors and Overcoming Their Effects in Bleeding Patients. American Journal Of Clinical Pathology 2013, 140: 610-622. PMID: 24124139, DOI: 10.1309/ajcp9vjs6kuknchw.Peer-Reviewed Original ResearchConceptsDirect thrombin inhibitorAvailable direct thrombin inhibitorThrombin inhibitorsDegree of anticoagulationLife-threatening bleedsExperimental animal modelsSupportive careBleeding patientsCase reportClinical trialsFactor concentratesRoutine coagulationAnticoagulant effectPharmacologic propertiesAnimal modelsThrombin timeTransfusion productsPathology consultationAnticoagulationDrug concentrationsLaboratory assessmentNewer assaysDrug removalBleedingPrimary author
2009
Improved plasma removal efficiency for therapeutic plasma exchange using a new apheresis platform
Tormey CA, Peddinghaus ME, Erickson M, King KE, Cushing MM, Bill J, Goodrich T, Snyder EL. Improved plasma removal efficiency for therapeutic plasma exchange using a new apheresis platform. Transfusion 2009, 50: 471-477. PMID: 19804570, DOI: 10.1111/j.1537-2995.2009.02412.x.Peer-Reviewed Original ResearchConceptsSignificant adverse eventsCellular countsPatients D-dimerPlasma-exchange programPlasma removal efficiencyTherapeutic plasma exchangePrimary outcome measureFluid balance measurementsComplement cascade activationPatient's coagulationSecondary outcomesAdverse eventsPlasma exchangeAnticoagulant usageD-dimerClinical trialsFluid replacementOutcome measuresFluid balanceCoagulation systemCOBE Spectra platformFree hemoglobinStudy designWaste plasmaNew apheresis deviceClinical trials for pathogen reduction in transfusion medicine: A review
McClaskey J, Xu M, Snyder EL, Tormey CA. Clinical trials for pathogen reduction in transfusion medicine: A review. Transfusion And Apheresis Science 2009, 41: 217-225. PMID: 19793679, DOI: 10.1016/j.transci.2009.09.008.Peer-Reviewed Original ResearchConceptsClinical trialsBlood productsDonor screening programsDonor blood productsRisk of transmissionInfective donorsTransfusion recipientsScreening programClinical settingInfectious diseasesTransfusion medicineTesting regimensPI treatmentTrialsScreening assaysRiskPathogensPotential toxicityPromising strategyDetection of pathogensRegimensPathogen reductionSensitive methodDiseaseRecipients